Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NRX PHARMACEUTICALS, INC.

(NRXP)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
0.6754 USD   +3.91%
09/19NRX PHARMACEUTICALS, INC.(NASDAQGM : NRXP) dropped from S&P Global BMI Index
CI
09/08NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference
PR
08/22NRX PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NRx Pharmaceuticals Says FDA Declines Emergency Use Authorization for COVID-19-Driven Respiratory Failure Therapy

07/01/2022 | 08:00am EDT


© MT Newswires 2022
All news about NRX PHARMACEUTICALS, INC.
09/19NRX PHARMACEUTICALS, INC.(NASDAQGM : NRXP) dropped from S&P Global BMI Index
CI
09/08NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global ..
PR
08/22NRX PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/22NRx Pharmaceuticals, Relief Therapeutics Reach Tentative Settlement Over Zyesami Litiga..
MT
08/22Relief Therapeutics, NRx Pharmaceuticals Secure Tentative Settlement Over Aviptadil Dis..
MT
08/15NRX PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/15NRx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
08/15NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Fo..
PR
08/12NRX PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
08/12NRX PHARMACEUTICALS : Non-Reliance on Previously Issued Financial Statements and Completed..
PU
More news
Analyst Recommendations on NRX PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 45,7 M 45,7 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees -
Free-Float 56,6%
Chart NRX PHARMACEUTICALS, INC.
Duration : Period :
NRx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NRX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,68 $
Average target price 2,00 $
Spread / Average Target 196%
Managers and Directors
Stephen H. Willard Chief Executive Officer & Director
Seth L. van Voorhees Chief Financial Officer & Treasurer
Jonathan C. Javitt Chairman & Chief Executive Officer
Robert Besthof Chief Commercial Officer & Head-Operations
Patrick J. Flynn Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NRX PHARMACEUTICALS, INC.-85.87%46
MODERNA, INC.-51.32%48 368
IQVIA HOLDINGS INC.-32.86%35 330
LONZA GROUP AG-41.68%33 599
SEAGEN INC.-9.96%25 673
ALNYLAM PHARMACEUTICALS, INC.18.40%24 099